SCHEMBL19090802

SCHEMBL19090802

CC(C)NC[C@@H](O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 3/20 0.42
KDM4A O75164 2/20 0.42
KDM4C Q9H3R0 2/20 0.42
KDM2A Q9Y2K7 2/20 0.42
TET3 O43151 1/20 0.42
OR51E2 Q9H255 1/20 0.42
GPR84 Q9NQS5 3/20 0.41
FFAR1 O14842 1/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
BLM P54132 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
TP53 P04637 2/20 0.41
ADRB2 P07550 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7402442 1.00 TET2 (0.42) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL7402444 1.00 TET2 (0.42) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL26510054 0.81 TET2 (0.44) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL25453271 0.80 ADRB2 (0.37) BLMADRB2MEN1KMT2ALMNA
SCHEMBL7572413 0.78 TET2 (0.37) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL9748639 0.77 APAF1 (0.53) KDM4EPOLBMAPTBLMTDP1
SCHEMBL10767735 0.77 APAF1 (0.53) KDM4EPOLBMAPTBLMTDP1
SCHEMBL20988200 0.76 GPR84 (0.43) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL20988012 0.76 GPR84 (0.43) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL19090975 0.76 OR51E2 (0.39) TET2KDM4AKDM4CKDM2ATET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212155-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-20210053946-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-02-25 US disclosed
US-10710986-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-14 US disclosed
US-20190270727-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2019-09-05 US disclosed
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212155-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 TET2 1220/4885KDM4A 1338/4885KDM4C 1309/4885
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE ERG28, RPL23, RPL10 TET2 2632/4885KDM4A 2418/4885KDM4C 2223/4885
US-20210053946-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 TET2 1220/4885KDM4A 1338/4885KDM4C 1309/4885
US-10710986-B2 PD-1/PD-L1 inhibitors PDCD1, CD274, PDCD1LG2 TET2 1220/4885KDM4A 1338/4885KDM4C 1309/4885
US-20190270727-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 TET2 1220/4885KDM4A 1338/4885KDM4C 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.